Boston Scientific Corporation (BSX) analyst actions
Rating and price-target actions on BSX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BSX overview →
2 measured BSX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module | Press release | -0.31% | +0.25% | |
| Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation | Press release | +0.90% | +1.83% |
Keep exploring
More BSX: earnings → · SEC filings → · BSX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Illumina, Inc. (ILMN) | 914 | +0.02% | 51% |
| Twist Bioscience Corporation (TWST) | 914 | -0.01% | 50% |
| Concert Pharmaceuticals, Inc. (CNCE) | 911 | 0.00% | 48% |
| TROVAGENE (TROV) | 906 | -0.52% | 40% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.